Clinical Trials Logo
  1. Home
  2. Severe Sepsis
  3. NCT02739373
  4. Details
NCT02739373 Clinical Trial

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Severe Sepsis Clinical Trial

Official title:
Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02739373
Other study ID # AI006-003
Secondary ID
Status Completed
Phase Phase 1
First received April 8, 2016
Last updated February 5, 2018
Start date April 18, 2016
Est. completion date December 14, 2016

Study information
Verified date February 2018
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.

Recruitment information / eligibility
Status Completed
Enrollment 76
Est. completion date December 14, 2016
Est. primary completion date December 14, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

- Healthy, males and females, 18 to 55 years of age, inclusive

- Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive

- Women of childbearing potential (WOCBP) must have negative serum pregnancy test (performed for all females; minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to start of study drug

Exclusion Criteria:

- Any significant acute or chronic medical illness

- History of diabetes mellitus, severe hypertriglyceridemia, acute or chronic pancreatitis, pancreatic exocrine disorder

- History of autoimmune disease

- Any known skin condition that would affect subcutaneous dosing

- Positive blood screen for hepatitis C antibody (HCV Ab), hepatitis B surface antigen (HBsAg), or HIV -1 and HIV -2 antibody

Other protocol defined inclusion/exclusion criteria could apply

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• BMS-986189

Other:
• Placebo

Locations
Country Name City State
United States Covance Clinical Research Unit, Inc. Evansville Indiana

Sponsors (1)
Lead Sponsor Collaborator
Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Maximum observed concentration (Cmax) Day 1 to Day 30
Primary Time of maximum observed concentration (Tmax) Day 1 to Day 30
Primary Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(O-T)) Day 1 to Day 30
Primary Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) Day 1 to Day 30
Primary Half Life (T-HALF) Day 1 to Day 30
Primary Total Body Clearance (CLT/F) Day 1 to Day 30
Primary Apparent volume of distribution at steady state (Vss/F) Day 1 to Day 30
Primary Deaths leading to discontinuation Day 1 to Day 30
Primary Adverse events (AEs) leading to discontinuation Day 1 to Day 30
Primary Serious adverse events (SAEs) leading to discontinuation Day 1 to Day 30
Primary Lab abnormalities leading to discontinuation Day 1 to Day 30
See also
  Status Clinical Trial Phase
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Completed NCT02539147 - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis N/A
Completed NCT01932814 - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful? N/A
Completed NCT01929772 - German Lactat Clearance in Severe Sepsis N/A
Completed NCT01449721 - Preemptive Resuscitation for Eradication of Septic Shock N/A
Active, not recruiting NCT01162109 - Zinc Therapy in Critical Illness Phase 1
Not yet recruiting NCT01211899 - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock N/A
Completed NCT00934011 - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections N/A
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00463645 - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients N/A
Completed NCT02361528 - GM-CSF to Decrease ICU Acquired Infections Phase 3
Completed NCT02734550 - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis N/A
Completed NCT02973243 - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Completed NCT01945983 - Early Use of Norepinephrine in Septic Shock Resuscitation N/A
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A

External Links